Research Topics
| Bryan LauSummaryAffiliation: Johns Hopkins Bloomberg School of Public Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional studyBryan Lau
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N, Wolfe Street, Baltimore, Maryland 21205, USA
AIDS Res Ther 7:25. 2010..We assessed whether routinely collected clinical markers could improve prediction of concurrent HIV RNA levels...- Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entryBryan Lau
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Stat Med 30:654-65. 2011..An application to the Women's Interagency HIV Study is provided to investigate injection drug use and the time to either the initiation of effective antiretroviral therapy, or clinical disease progression as a competing event... 
Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infectionBryan Lau
Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 39:620-5. 2005..These results support the potential utility of these markers for monitoring HIV-infected people in resource-limited regions, but critical levels and rates of decline of markers for such regions remain to be defined...- Competing risk regression models for epidemiologic dataBryan Lau
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
Am J Epidemiol 170:244-56. 2009..71, 95% confidence interval: 1.37, 2.13 and (sd)RH = 2.01, 95% confidence interval: 1.62, 2.51). Methods for competing risks should be used by epidemiologists, with the choice of method guided by the scientific question... - Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studiesBryan Lau
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Epidemiology 20:664-72. 2009..No studies have evaluated the impact of the frequency of marker measurements for either their predictive value of mortality or how they may influence inference of the effect of therapy initiation in analyses from observational data... - Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected menBryan Lau
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
AIDS 17:2035-44. 2003..These results suggest that TLC and Hgb might be useful for monitoring disease progression in resource-limited settings... - C-reactive protein is a marker for human immunodeficiency virus disease progressionBryan Lau
Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
Arch Intern Med 166:64-70. 2006..Limited data on acute-phase C-reactive protein (CRP) levels in human immunodeficiency virus (HIV) infection exist... - Evaluating competing adverse and beneficial outcomes using a mixture modelBryan Lau
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
Stat Med 27:4313-27. 2008.... - Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survivalRobyn C Neblett
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Womens Health (Larchmt) 20:279-86. 2011..We sought to determine factors associated with alcohol use among HIV-infected women engaged in clinical care and if baseline alcohol use was associated with time to combination antiretroviral therapy (cART) and death in this population... - Virologic and immunologic response to HAART, by age and regimen classKeri N Althoff
Johns Hopkins University, Baltimore, Maryland 21287, USA
AIDS 24:2469-79. 2010..To determine the impact of age and initial HAART regimen class on virologic and immunologic response within 24 months after initiation... - Alcohol consumption and CD4 T-cell count response among persons initiating antiretroviral therapyStefan Kowalski
Department of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 61:455-61. 2012..We evaluated the longitudinal association of alcohol use with immunologic response to combination antiretroviral therapy (ART) among HIV-infected individuals... - HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug usersMegan L Salter
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
Clin Infect Dis 53:1256-64. 2011.... - Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infectionGeetanjali Chander
Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 43:411-7. 2006..We examined the independent effect of alcohol and combined effects of drug and alcohol use on antiretroviral (ART) utilization, adherence, and viral suppression in an urban cohort of HIV-infected individuals... - Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1Megan Wind-Rotolo
Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
J Infect Dis 199:1301-9. 2009..Although resistant viruses fade to undetectable levels in plasma, they may persist as stably integrated proviruses within the latent reservoir in resting CD4(+) T cells, potentially complicating future treatment... - Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3Bryan Lau
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 44:179-87. 2007..To quantify cause-specific mortality risk attributable to non-AIDS-related and AIDS-related causes before and after the advent of highly active antiretroviral therapy (HAART)... - Methods for the analysis of continuous biomarker assay data with increased sensitivityBryan Lau
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
Epidemiology 15:724-32. 2004.... - Interval and clinical cohort studies: epidemiological issuesBryan Lau
Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, USA
AIDS Res Hum Retroviruses 23:769-76. 2007..The interval and clinical cohort designs are distinguished and the advantages and disadvantages inherent in each design are discussed... - Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north americaAlison G Abraham
Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Suite E7640, Baltimore, MD 21205, USA
Am J Epidemiol 174:727-35. 2011.... - Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burdenStephen R Cole
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
Am J Epidemiol 171:198-205. 2010..Copy-years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond traditional single measures of viremia... - Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trialGregory M Lucas
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ann Intern Med 152:704-11. 2010..Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings... 
Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug usersTsung Chieh Fu
aDepartment of Epidemiology, University of Washington School of Public Health, Seattle, Washington bDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin cDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland dSchool of Nursing, University of California at San Francisco, San Francisco, Califonis eDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
AIDS 26:2383-91. 2012..To evaluate whether HAART is associated with subsequent sexual and drug-related risk behavior compensation among injection drug users (IDUs)...- Exceeding the limits of liver histology markersShruti H Mehta
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 1830 E Monument St, Room 455 ID, Baltimore, MD 21287, USA
J Hepatol 50:36-41. 2009..We characterized the magnitude of the impact of error in the "gold standard" on the observed diagnostic accuracy of surrogate markers... - Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine careRobert C Kalayjian
Metro Health Medical Center, Cleveland, Ohio, USA
AIDS 26:1907-15. 2012.... - Importance of age of onset in pancreatic cancer kindredsKieran A Brune
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
J Natl Cancer Inst 102:119-26. 2010..Young-onset cancer is a hallmark of many familial cancer syndromes, yet the implications of young-onset disease in predicting risk of pancreatic cancer among familial pancreatic cancer (FPC) kindred members remain unclear... - Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two racesGregory M Lucas
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicines, Baltimore, Maryland, USA
J Infect Dis 197:1548-57. 2008..Little is known about the racial differences in the incidence and progression of HIV-related chronic kidney disease (CKD) that underlie African American-white disparities in HIV-related end-stage renal disease (ESRD)... - Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapyStephen J Gange
Department of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
AIDS 17:119-21. 2003